Renaissance Technologies LLC Sells 16,800 Shares of Leap Therapeutics, Inc. (NASDAQ:LPTX)

Renaissance Technologies LLC lowered its stake in shares of Leap Therapeutics, Inc. (NASDAQ:LPTX) by 14.7% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 97,670 shares of the company’s stock after selling 16,800 shares during the quarter. Renaissance Technologies LLC owned 0.38% of Leap Therapeutics worth $191,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Key Client Fiduciary Advisors LLC grew its stake in Leap Therapeutics by 22.2% in the 2nd quarter. Key Client Fiduciary Advisors LLC now owns 284,856 shares of the company’s stock valued at $558,000 after purchasing an additional 51,838 shares during the period. Acadian Asset Management LLC grew its stake in Leap Therapeutics by 349.3% in the 1st quarter. Acadian Asset Management LLC now owns 282,413 shares of the company’s stock valued at $750,000 after purchasing an additional 219,563 shares during the period. Finally, Vanguard Group Inc. grew its stake in Leap Therapeutics by 111.7% in the 1st quarter. Vanguard Group Inc. now owns 867,708 shares of the company’s stock valued at $2,308,000 after purchasing an additional 457,904 shares during the period. Institutional investors own 30.46% of the company’s stock.

Analyst Ratings Changes

LPTX has been the subject of a number of recent analyst reports. HC Wainwright restated a “buy” rating and issued a $5.50 price objective on shares of Leap Therapeutics in a research note on Tuesday, August 13th. Rodman & Renshaw initiated coverage on Leap Therapeutics in a research report on Friday, June 28th. They set a “buy” rating and a $8.00 price target on the stock. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $10.40.

Leap Therapeutics Price Performance

Shares of NASDAQ LPTX opened at $2.31 on Friday. The business’s fifty day moving average price is $2.63 and its 200-day moving average price is $2.52. The stock has a market capitalization of $59.14 million, a PE ratio of -0.97 and a beta of 0.27. Leap Therapeutics, Inc. has a one year low of $1.31 and a one year high of $5.00.

Leap Therapeutics (NASDAQ:LPTX) last issued its quarterly earnings data on Monday, August 12th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.10). As a group, equities analysts expect that Leap Therapeutics, Inc. will post -1.84 EPS for the current fiscal year.

Leap Therapeutics Company Profile

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.